跳至主要内容
临床试验/EUCTR2014-001619-37-NL
EUCTR2014-001619-37-NL进行中(未招募)1 期

Contrast enhanced Diffusion-weighted Magnetic Resonance Imaging for detection of pathologic lymph nodes in ovarian cancer – a feasibility study. - MILO

Maastricht University Medical Centre0 个研究点目标入组 20 人开始时间: 2014年6月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Non-pregnant female
  • Expected FIGO stage IIB-IV epithelial ovarian carcinoma
  • Scheduled for primary debulking surgery
  • Written informed consent
  • At least 18 years of age.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • Patients estimated to have more benefit from neoadjuvant chemotherapy
  • Ineligibility to undergo MRI
  • Ineligibility to receive contrast agent
  • Previous para-aortic or pelvic lymphadenectomy
  • History of a malignant tumour.
  • Pregnant or lactating patients.

研究者

发起方
Maastricht University Medical Centre

相似试验